Clinical Trials Logo

Stargardt Disease 1 clinical trials

View clinical trials related to Stargardt Disease 1.

Filter by:
  • None
  • Page 1

NCT ID: NCT06300476 Active, not recruiting - Stargardt Disease 1 Clinical Trials

Safety and Efficacy of a Single Subretinal Injection of JWK006 Gene Therapy in Subjects With Stargardt Disease(STGD1)

Start date: November 20, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of the study is to assess the safety and efficacy of JWK006 in Stargardt Disease(STGD1). JWK006 is packed by adeno-associated virus vector that expressing ABCA4 gene.

NCT ID: NCT05674058 Recruiting - Stargardt Disease Clinical Trials

Function and Imaging Assessments for G1961E-associated Stargardt Disease

FIRSTORBIT
Start date: November 1, 2022
Phase:
Study type: Observational

Some phenotypes of Stargardt disease are rather distinct. This includes the 'bull's eye maculopathy' phenotype associated with the frequent ABCA4 G1961E variant. In anticipation of a treatment trial, this natural history study aims to compare functional and structural outcome measures systematically.

NCT ID: NCT05258032 Recruiting - Clinical trials for Retinitis Pigmentosa

Structural and Functional Characterization of Rare Ocular Diseases

RADIS
Start date: November 24, 2021
Phase:
Study type: Observational

Rare ocular diseases (ROD) are a heterogeneous group of ocular diseases that affect very few people and, generally, for which no tretament is available. An important subgroup of these diseases are inherited retinal degenerations. In this study we focus on understanding the natural history of different ROD that affect the posterior segment.

NCT ID: NCT05244304 Active, not recruiting - Stargardt Disease 1 Clinical Trials

Study to Evaluate the Safety and Efficacy of Tinlarebant in the Treatment of Stargardt Disease in Adolescent Subjects Lesion(s) in Adolescent Subjects With STGD1

DRAGON
Start date: March 28, 2022
Phase: Phase 3
Study type: Interventional

The primary objective of this trial is to assesses the efficacy of tinlarebant in slowing the rate of growth of atrophic lesion(s) in adolescent subjects with STGD1

NCT ID: NCT04489511 Completed - Stargardt Disease-1 Clinical Trials

Study of STG-001 in Subjects With Stargardt Disease

Start date: October 1, 2020
Phase: Phase 2
Study type: Interventional

This is an open-label, multicenter study in subjects with Stargardt disease, comparing 2 doses of STG-001 with regard to safety, pharmacokinetics and pharmacodynamics.

NCT ID: NCT04281732 Recruiting - Clinical trials for Retinitis Pigmentosa

Visual Performance Measures in a Virtual Reality Environment for Assessing Clinical Trial Outcomes in Those With Severely Reduced Vision

Start date: October 1, 2018
Phase:
Study type: Observational

Purpose: To validate a newly developed battery of performance-based tests of visual function to be presented using virtual reality. The tests are intended as potential outcome measures for clinical trials of treatments of eye disease: they measure visual performance in patients with low vision on visual tasks that a relevant for daily life.

NCT ID: NCT03772938 Enrolling by invitation - Clinical trials for Retinitis Pigmentosa

Stem Cells Therapy in Degenerative Diseases of the Retina

Start date: December 13, 2018
Phase: Phase 1
Study type: Interventional

The purpose of this study is to test the safety and effectiveness of an autologous bone marrow-derived stem/progenitor cells administered intravitreously in the subjects with degenerative diseases of the retina.

NCT ID: NCT03364153 Active, not recruiting - Stargardt Disease 1 Clinical Trials

Zimura Compared to Sham in Patients With Autosomal Recessive Stargardt Disease (STGD1)

Start date: January 12, 2018
Phase: Phase 2
Study type: Interventional

To evaluate the safety and efficacy of Zimura™ (complement factor C5 inhibitor) compared to Sham in subjects with autosomal recessive Stargardt disease 1 (STGD1).

NCT ID: NCT03297515 Completed - Stargardt Disease 1 Clinical Trials

Therapeutic Potential of Omega-3 Fatty Acids Supplementation in Dry Macular Degeneration and Stargardt Disease

MADEOS
Start date: May 15, 2019
Phase: N/A
Study type: Interventional

Prospective, randomised, double-blind study to assess the Therapeutic Potential of Omega-3 Fatty Acids Supplementation in Dry Macular Degeneration and Stargardt Disease (Macular Degeneration Omega-3 Study - MADEOS.